ULTOMIRIS / GMG

 The long-acting complement inhibitor ULTOMIRIS (ravulizumab-cwvz) was approved in the Spring of 2002 by the FDA to treat most adults with generalized myasthenia gravis (gMG). With an accelerated timeline, I co-lead multiple creative teams to develop and launch separate creative campaigns for HCP, DTC and Global simultaneously. Cynthia was the sole creative responsible for developing this concept and seeing it through the production, the “Ultomiris Is” DTC campaign successfully launched the brand and is currently still running with new executions.